Cell Reports (Jul 2019)

Monocytes Acquire the Ability to Prime Tissue-Resident T Cells via IL-10-Mediated TGF-β Release

  • Elizabeth A. Thompson,
  • Patricia A. Darrah,
  • Kathryn E. Foulds,
  • Elena Hoffer,
  • Alayna Caffrey-Carr,
  • Sophie Norenstedt,
  • Leif Perbeck,
  • Robert A. Seder,
  • Ross M. Kedl,
  • Karin Loré

Journal volume & issue
Vol. 28, no. 5
pp. 1127 – 1135.e4

Abstract

Read online

Summary: Using non-human primates (NHPs), mice, and human primary cells, we found a role for interleukin-10 (IL-10) in the upregulation of the tissue-resident memory T cell (TRM) marker CD103. In NHPs, intravenous, but not subcutaneous, immunization with peptide antigen and an adjuvant combining an agonistic anti-CD40 antibody plus poly(IC:LC) induced high levels of CD103+ TRMs in the lung, which correlated with early plasma IL-10 levels. Blocking IL-10 reduced CD103 expression on human T cells stimulated in vitro with the adjuvant combination as well as diminished CD103 on lung-resident T cells in vivo in mice. Monocyte-produced IL-10 induced the release of surface-bound transforming growth factor β (TGF-β), which in turn upregulated CD103 on T cells. Early TGF-β imprinted increased sensitivity to TGF-β restimulation, indicating an early commitment of the T cell lineage toward TRMs during the priming stage of activation. IL-10-mediated TGF-β signaling may therefore have a critical role in the generation of TRM following vaccination. : Thompson et al. outline a role for early IL-10 following immunization in the release of TGF-β and subsequent differentiation of CD103+ TRMs. Using a combination of non-human primate, human, and murine systems, the authors demonstrate that blocking IL-10 reduces CD103 expression, whereas delivery of IL-10 can augment a CD103+ phenotype. Keywords: tissue-resident memory T cells, vaccine, anti-CD40, toll-like receptor, IL-10, TGF-beta, monocyte, T cell, non-human primate, TRM